Structured Review

Gilead Sciences kaletra
Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and <t>Kaletra</t> experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Kaletra, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kaletra/product/Gilead Sciences
Average 97 stars, based on 1 article reviews
Price from $9.99 to $1999.99
kaletra - by Bioz Stars, 2021-09
97/100 stars

Images

1) Product Images from "Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease"

Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Journal: Liver International

doi: 10.1111/liv.12699

Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Figure Legend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

Techniques Used: Mouse Assay

2) Product Images from "Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease"

Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Journal: Liver International

doi: 10.1111/liv.12699

Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Figure Legend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

Techniques Used: Mouse Assay

3) Product Images from "Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease"

Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Journal: Liver International

doi: 10.1111/liv.12699

Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Figure Legend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

Techniques Used: Mouse Assay

4) Product Images from "Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease"

Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Journal: Liver International

doi: 10.1111/liv.12699

Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Figure Legend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

Techniques Used: Mouse Assay

5) Product Images from "Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease"

Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Journal: Liver International

doi: 10.1111/liv.12699

Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Figure Legend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

Techniques Used: Mouse Assay

6) Product Images from "Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease"

Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Journal: Liver International

doi: 10.1111/liv.12699

Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Figure Legend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

Techniques Used: Mouse Assay

7) Product Images from "Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease"

Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Journal: Liver International

doi: 10.1111/liv.12699

Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
Figure Legend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

Techniques Used: Mouse Assay

Related Articles

other:

Article Title: Uptake and outcomes of a novel community‐based HIV post‐exposure prophylaxis (PEP) programme in rural Kenya and Uganda
Article Snippet: Competing InterestsAll authors receive grant support from the NIH, Gilead Sciences provided Truvada for the SEARCH study, CAK has received grant support to institution from Gilead Research Scholars Program in HIV.

Article Title: Incident Cases of Sexually Transmitted Infections among Users of Pre-Exposure Prophylaxis for HIV Prevention in Honolulu, Hawai‘i
Article Snippet: To date, only one study, Pre-Exposure Option for Reducing HIV in the UK (PROUD), an open-label randomized clinical trial comparing immediate to deferred daily Truvada for HIV-negative gay men, was explicitly designed to detect changes in sexual risk behavior by comparing MSM in the United Kingdom who knew they were on PrEP (randomized to immediate start) to those who knew they were not on PrEP (randomized to a 1-year delay).

Article Title: Novel GVHD resistant humanized-PBMC mouse model for preclinical HIV research
Article Snippet: The cART regimen consisting of Truvada® [tenofovir disoproxil fumarate (TDF; 300 mg/tablet), emtricitabine (FTC; 200 mg/tablet) (Gilead Sciences)] and Isentress® [raltegravir (RAL; 400 mg/tablet) (Merck)], scaled down to the equivalent mouse dosage using the appropriate conversion factor, was administered in a drinking water formulation (sweetened water gel, Medidrop® Sucralose, ClearH20).

Article Title: Understanding demand for PrEP and early experiences of PrEP use among young adults in rural Kenya and Uganda: A qualitative study
Article Snippet: Gill K, Pidwell T, Dietrich J, Gray G, Bennie T, Myer L, et al. A demonstration open label study to assess the acceptability, safety and use of Truvada pre-exposure prophylaxis in healthy, HIV-uninfected adolescents, 15–19 years of age.

Article Title: The Promise of the Dual Prevention Pill: A Framework for Development and Introduction
Article Snippet: Ideally, the DPP will be marketed in blister packaging to look as similar as possible to a contraceptive regimen (recognizing that Truvada is a much larger tablet than any COC).

Article Title: Virostatika im Notfall
Article Snippet: B. Truvada).

Article Title: Awareness, Utilization, and Preferences for Traditional and Contemporary HIV Prevention Strategies Among Facebook and Instagram-Using MSM in the United States
Article Snippet: Awareness and utilization of different HIV prevention strategies were assessed by asking participants to select “I know about this” and “I currently do this” for each of the following 10 strategies: (i) regularly testing for HIV (e.g., every 6 months to 1 year), (ii) regularly testing and getting treated for other STIs (e.g., chlamydia, gonorrhea, syphilis), (iii) limiting the number of sex partners, (iv) encouraging partners to get tested and treated for HIV and other STIs, (v) discussing HIV and other STI status with partners, (vi) only having sex with known HIV-negative partners, (vii) engaging in sexual activities other than anal sex (e.g., oral sex, mutual masturbation), (viii) always using condoms during anal sex, (ix) taking PrEP every day to prevent HIV (e.g., Truvada®), (x) taking PEP for 28 days after possibly being exposed to HIV.

Article Title: Incident Cases of Sexually Transmitted Infections among Users of Pre-Exposure Prophylaxis for HIV Prevention in Honolulu, Hawai‘i
Article Snippet: Food and Drug Administration Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Gilead Sciences kaletra
    Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and <t>Kaletra</t> experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P
    Kaletra, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kaletra/product/Gilead Sciences
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    kaletra - by Bioz Stars, 2021-09
    97/100 stars
      Buy from Supplier

    Image Search Results


    Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

    Journal: Liver International

    Article Title: Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

    doi: 10.1111/liv.12699

    Figure Lengend Snippet: Antiretroviral regimens associated with reduction in serum liver enzyme levels from baseline. (A) After 4 weeks of treatment, only mice receiving Truvada and Kaletra experienced a significant mean reduction in alkaline phosphatase levels as compared to placebo, whereas by the end of 12 weeks therapy mice treated with regimens containing Truvada with or without Kaletra experienced significant reduction. (B) A significant reduction in serum alanine transaminase levels was observed in mice receiving Truvada and Kaletra but not Combivir and Kaletra [Combivir (zidovudine and lamivudine), Truvada (tenofovir and emtricitabine), Kaletra (lopinavir and ritonavir); data shown as means ± SEM; * P

    Article Snippet: Conflict of interest: AbbVie and Gilead Sciences are providing medications for ongoing clinical trial using Truvada and Kaletra for patients with PBC.

    Techniques: Mouse Assay